As of 2014, firm appears to be no longer operational. Accord was developing nitric oxide (NO) sensors that detect free and bound NO, including s-nitrosothiols, in blood. Accord also specialized in the stabilization of these reactive NO species to enable accurate measurement representative of physiologic conditions. The company had been venture-funded, and collaborating with the Cleveland Clinic. Accord had planned to commercialize sensors for the research market in 2013 and to pursue in-vitro diagnostics indications with partners. Potential applications include cardiovascular, endocrine, inflammatory and hypertensive diseases. Accord held expertise in NO biochemistry and analytics, electrochemistry applied to life sciences applications, medical device development and biomarker validation.
